Are you a health professional in Europe?

 

By accessing this website, you accept and agree to the following terms and conditions. In order to comply with Spanish Regulations on Advertising of Medicinal Products for Human Use, we must inform you that the information on the “Yondelis®” area of this website is intented for qualified health care professionals with specialized training. If you are not a healthcare professional, please, refrain from accessing this area.

Oncology pipeline

PharmaMar develops and commercializes YONDELIS® in Europe and has three clinical-stage drug candidates under development for several types of solid and hematological cancers, Aplidin ®, Lurbinectedin, and PM184.

Science & Innovation

Our strong commitment to oncology translational research along with our deep understanding of the marine biodiversity of our oceans is placing us at the head of marine biotechnology.

Newsroom

If you need information about the company, our clinical trials, corporate images or multimedia, visit our newsroom